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Abstract
The role of structural brain magnetic resonance imaging (MRI) is becoming more and more emphasized in the early
diagnostics of Alzheimer’s disease (AD). This study aimed to assess the improvement in classification accuracy that can be
achieved by combining features from different structural MRI analysis techniques. Automatically estimated MR features
used are hippocampal volume, tensor-based morphometry, cortical thickness and a novel technique based on manifold
learning. Baseline MRIs acquired from all 834 subjects (231 healthy controls (HC), 238 stable mild cognitive impairment (S-
MCI), 167 MCI to AD progressors (P-MCI), 198 AD) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
were used for evaluation. We compared the classification accuracy achieved with linear discriminant analysis (LDA) and
support vector machines (SVM). The best results achieved with individual features are 90% sensitivity and 84% specificity
(HC/AD classification), 64%/66% (S-MCI/P-MCI) and 82%/76% (HC/P-MCI) with the LDA classifier. The combination of all
features improved these results to 93% sensitivity and 85% specificity (HC/AD), 67%/69% (S-MCI/P-MCI) and 86%/82% (HC/
P-MCI). Compared with previously published results in the ADNI database using individual MR-based features, the presented
results show that a comprehensive analysis of MRI images combining multiple features improves classification accuracy and
predictive power in detecting early AD. The most stable and reliable classification was achieved when combining all
available features.
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Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
globally and one of the major healthcare issues of the future. It has
been estimated that during the next four decades the prevalence of
AD will quadruple from 27 to 106 million by which time 1 in 85
persons worldwide will be living with the disease [1]. Even a
modest delay of one year in disease onset and progression could
reduce the number of cases by 9 million [1]. Interventions are
postulated to be most effective when directed at patients at the
earliest stages of the disease, which underlines the importance of
early diagnosis of AD [2]. Mild cognitive impairment (MCI) is a
heterogeneous syndrome that increases the risk of developing AD
markedly [3]. However, not all MCI subjects convert to AD and
some may even return to normal cognition [4].
The search for reliable biomarkers of AD-type pathology and
predictors of disease progression among MCI subjects is ongoing.
AD is characterized by neurofibrillary tangles and amyloid plaques
in the brain [5]. Degenerative changes in the human neurotrans-
mitter system lead to atrophy in selected brain regions [6]. The
most promising candidate biomarkers are the ones derived from
structural and functional neuroimaging as well as those measured
in cerebrospinal fluid (CSF) and plasma [7]. Amyloid-based
measures like the CSF-peptide Ab42 and the uptake of the PiB
tracer on positron emission imaging (PET) show the earliest AD-
type changes [7]. However, there is evidence that the number of
amyloid plaques reach their saturation levels already by the time
patients have clinically apparent symptoms of cognitive impair-
ment [8,9], whereas atrophy, neuronal loss, synaptic loss, and the
number of tangles increase with severity of illness [10]. These
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used as longitudinal markers of AD type pathology, they seem to
offer only limited insight into which MCI subjects will most likely
convert to AD in the near future. In a recently published dynamic
model of biomarker behavior in the AD spectrum, biomarkers
based on structural magnetic resonance imaging (MRI) have been
shown to be correlated with a progression from MCI to AD [11].
Such biomarkers could therefore improve the accuracy of early
AD diagnostics and reduce especially the amount of false positive
diagnoses. Besides providing chance for a more focused and earlier
intervention, structural MRI biomarkers of AD could also aid the
development of new disease-modifying drugs by acting as surrogate
markers of disease progression, reduce the number of subjects
needed to detect significant drug effect and provide quantitative
measures of treatment benefits [12].
It has been shown that the early diagnostics of AD can be
improved by using multiple different biomarkers simultaneously.
Usually these studies have combined MRI-based markers with
biomarkers based on positron emission tomography (PET) [13,14],
cerebrospinal fluid (CSF) [15,16] or both [17–19]. Achieved
results vary from no additional benefit [15,17] to significant
improvement [13,14,16,20]. However, availability of all three
biomarkers (CSF, PET, MRI) is not very common in clinical
practice since obtaining all measures is laborious for the patient
and clinician, induces delays and increases the costs of the
diagnosis significantly. Furthermore, measurements obtained from
CSF and PET are considered invasive. Recent studies focusing on
only structural MRI have reached correct classification accuracys
(CCR) of 76–94% in identifying healthy controls (HC) from
patients with AD and 64–82% in predicting which MCI subjects
will convert to AD in the imminent future [21–27]. The high
variation in these results can be attributed to differences in study
populations as well as evaluation designs. With the Alzheimer’s
Disease Neuroimaging Study (ADNI) [28], a large multi-center
study on MR imaging in AD has been established that is available
to the wider research community. Based on a large sub-group of
ADNI subjects, Cuingnet et al. [29] presented a comparison of ten
MRI-based feature extraction methods and their ability to
discriminate between clinically relevant subject groups. The ten
methods evaluated comprise five voxel-based methods, three
methods based on cortical thickness and two methods based on the
hippocampus. Best sensitivity/specificity values reported are 81%/
95% for AD vs HC, 70%/61% for S-MCI vs P-MCI and 73%/
85% for HC vs P-MCI.
In this paper we use the ADNI database to evaluate the ability
of the combination of different MR-based features to increase
classification accuracy. We evaluate the power of hippocampal
volume (HV), cortical thickness (CTH), tensor-based morphom-
etry (TBM) and features extracted from a recently proposed
manifold-based learning (MBL) framework to discriminate healthy
controls from subjects with AD and to predict conversion from
MCI to AD. For evaluation we used all 834 ADNI baseline images
that were available from the ADNI webpage. Compared to
previous work this paper aims at establishing the improvement in
accuracy and stability that can be achieved by combining more
than one MR-based feature. To the best of our knowledge it is the
first comprehensive study that analyzes MRI-derived features for
the full ADNI dataset. For direct comparison with the work by
Cuingnet et al. [29] we also evaluated all results on the subset used
in their work.
To test the influence of the classification method used, we utilized
both support vector machines (SVMs) and a linear discriminant
analys (LDA) to evaluate classification accuracy (CCR), sensitivity
(SEN) and specificity (SPE) in each experiment.
Materials and Methods
Subjects
In the ADNI study, brain MR images were acquired at regular
intervals after an initial baseline scan from approximately 200
cognitively normal older subjects (HC), 400 subjects with mild
cognitive impairment (MCI), and 200 subjects with early AD.
Detailled inclusion/exclusion criteria used for the different subject
groups in ADNI are defined in [30]. The AD group has scores
between 20–26 (inclusive) on the Mini-Mental State Examination
(MMSE) [31], and a Clinical Dementia Rating (CDR) [32] of 0.5
or 1.0. Furthermore, these subjects fulfil the NINCDS/ADRDA
criteria for probable AD [33]. MCI subjects included have MMSE
scores between 24–30 (inclusive), a memory complaint, have
objective memory loss measured by education adjusted scores on
Wechsler Memory Scale Logical Memory II, a CDR of 0.5,
absence of significant levels of impairment in other cognitive
domains, essentially preserved activities of daily living, and an
absence of dementia [30]. Healthy subjects have MMSE scores
between 24–30 (inclusive), a CDR of 0, are non-depressed, non
MCI, and nondemented. A more detailed description of the ADNI
study is given in Appendix S1.
All 834 ADNI subjects (231 HC, 238 S-MCI, 167 P-MCI, 198
AD) for which a 1.5T T1-weighted MRI scan at baseline was
available were included in this study. 167 subjects in the MCI
group converted to AD as of July 2011. We therefore
independently analysed progressive MCI (P-MCI) subjects and
subjects with a stable diagnosis of MCI (S-MCI).
Table 1 shows the demographics for the 834 study subjects.
Statistically significant differences in the demographics and clinical
variables between the study groups were assessed using Student’s
unpaired t-test. In this work, the difference was considered
statistically significant if pv0.05 if not stated otherwise. There
were more men than women in all other groups besides the AD
group. MMSE scores were significantly different in the pairwise
comparisons between all study groups. CDR scores of the HC and
AD groups are significantly different to the ones of the two MCI
groups. Healthy subjects had a significantly lower Geriatric
Depression Scale (GDS) compared to all other groups. Compared
to all other groups, AD subjects had significantly shorter education.
MRI Acquisition
Standard 1.5T screening/baseline T1-weighted images ob-
tained using volumetric 3D MPRAGE protocol with resolutions
Table 1. Subjects.
Group HC S-MCI P-MCI AD
N 231 238 167 198
Men 52% 66% 62% 52%
Age 76.02 (5.0) 74.85 (7.8) 74.6 (7.0) 75.68 (7.7)
MMSE 29.1* (1.0) 27.3* (1.8) 26.6* (1.7) 23.3* (2.0)
CDR 0 (0) 0.49 (0.05) 0.50 (0) 0.75 (0.25)
GDS 0.83* (1.14) 1.60 (1.42) 1.53 (1.30) 1.67 (1.42)
Education 16.0 (2.8) 15.6 (3.1) 15.7 (2.9) 14.7* (3.1)
APOE4 status
(e3e4/e4e4)
23%/2% 31%/8% 50%/16% 42%/18%
Months to
conversion
18.2 (10.1)
*means statistically significant different from all other groups.
doi:10.1371/journal.pone.0025446.t001
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|1.20 mm were included from the ADNI database. For detailed
information of the MRI protocols and preprocessing steps see [34].
Feature extraction
All fully automated feature extraction methods described below
were applied to images that were preprocessed by the ADNI
pipeline.
Hippocampal volume. Baseline hippocampal volumes
were measured using an approach based on fast and robust
multi-atlas segmentation [35,36]. In this approach, multi-atlas
label propagation is applied in combination with atlas selection to
obtain the hippocampus segmentation. A set of hippocampus
atlases is selected from a pool of atlas images according to image
similarity with the query image. After registering all atlases to the
query image, a spatial prior is generated from the multiple label
maps. This spatial prior is then used to obtain a final segmentation
based on an expectation maximization (EM) segmentation
algorithm [37].
Cortical thickness. CTH is measured in the baseline
T1-weighted structural MR images by using an automated
computational surface-based method developed at the McConnell
Brain Imaging Centre, Montreal Neurological Institute, McGill
University, Montreal, Canada (http://www2.bic.mni.mcgill.ca/)
[38]. Individual MRI volumes were registered to standard space
using the ICBM152 template [39]. Intensity non-uniformities were
corrected [40] before the final brain mask was calculated [41].
Tissues were segmented into white matter (WM), grey matter (GM)
and cerebrospinal fluid (CSF) using the INSECT-algorithm [42]
and the magnitude of PVE was estimated by using the trimmed
minimum covariance determinant (TMCD) method [43]. The
brains were divided automatically into two separate hemispheres
and the inner and outer surfaces of the cortex were extracted
according to intersections between WM and GM (white matter
surface, WMS) as well as GM and CSF (grey matter surface, GMS)
using the Constrained Laplacian-Based Automated Segmentation
with Proximities (CLASP) algorithm [44]. The inner surface was
first formed by deforming an ellipsoid polygon mesh to the shape of
the WMS. GMS was obtained by further expanding the inner
surface. Each polygon mesh surface consisted of 81,920 polygons
and 40,962 nodes per hemisphere. The thickness of the cortex was
defined at each linked node as the distance between the two
concentrically linked polygon meshes on the WMS and the GMS.
This t-link metric has been proven to be the simplest yet most
precise way to determine cortical thickness [38]. Although MR
images were transformed to standard space to allow for group
analysis, thickness calculations were performed in each subject’s
native space. Finally, cortical thickness maps were smoothed with a
20 mm FWHM diffusion smoothing kernel to improve the signal-
to-noise ratio and statistical power [45]. The described toolbox did
not achieve satisfactory results on some study subjects because of i)
failure in tissue segmentation and brain masking (48 subjects) and ii)
failure in partial volume effect estimation (59 subjects). As a result
the pipeline crashed and CTH measures were not obtained for 76
subjects (24 control, 35 MCI, 17 AD). Also the cortical model of 31
subjects (10 control, 13 MCI, 8 AD) was completely deformed and
thus unusable. For these 107 subjects the CTH features were
considered as missing values. CTHfeatures used in the classification
experiments are introduced below.
Tensor-based morphometry. The TBM analysis was
performed using a multi-template approach [46,47]. In TBM, a
template image is non-rigidly registered to a study image, and,
typically, the determinant of the Jacobian matrix (‘the Jacobian’) of
the deformation is used to measure the voxel-level morphometry.
Instead of using just one template image, we used 30 randomly
selected images (10 controls, 10 MCIs, and 10 ADs) from the
ADNI database as template images. The template images were
used also in the classification analysis to maximize the number of
subjects. Each template image was registered to a study image, and
Jacobian maps were computed for each template image. To
combine the results of multiple templates, all template images were
registered to the mean anatomical template generated from the 30
images, and all the results were normalized to this reference space
[47]. The combination of the results was performed by averaging
the ROI-wise feature values of all the templates as described in
detail below.
Manifold-based learning. In this machine learning
approach, non-linear dimensionality reduction with Laplacian
eigenmaps [48] is used to learn features to discriminate between
different subject groups. Laplacian eigenmaps estimates the low-
dimensional representation of a set of input images based on a
similarity graph that is defined with pairwise image similarities [48].
The hypothesis is that such a low-dimensional representation
captures the variability in the dataset in a more compact way than
pairwise image similarities directly. We estimate pairwise image
similarities from the intensity appearance in a region around
hippocampus and amygdala since both structures are known to be
affected by AD in an early stage. All images are aligned in a
template space using a coarse non-rigid registration (10 mm B-
spline control-point spacing, [49]). Such a coarse non-rigid
alignment ensures that corresponding brain structures are aligned
but still allows to measure subject-specific differences. After
performing dimensionality reduction, the first 20 dimensions of
the resulting manifold are used as features to perform classification
with the different methods used. More details on the theory and
application of this manifold learning approach can be found in
[20,50]. Figure 1 exemplarily shows a 2D embedding of a set of
ADNI images acquired from healthy controls and subjects withAD.
It can be seen that even two embedding dimensions give a relatively
good separationbetween both groups.Inourexperimentswe used a
higher dimensional space allowing better discrimination.
ROI-wise features for CTH and TBM
Both CTH and TBM analyses produce local (point-wise)
information, either on cortical thickness or the volume. Thus,
the number of original features is enormous, and to make the
classification more efficient and robust, the number of features has
to be reduced. We evaluated both features in a statistical region of
interest (ROI) defined as detailed in Appendix S2. Figures 2 and 3
show t-values for statistically significant differences between study
groups for TBM and CTH respectively. A detailed description of
the definition of these statistical ROIs is given in Appendix S2.
Study design
Table 2 presents an overview on the features calculated for all
834 available ADNI baseline images. All feature values were
corrected for age and gender using a linear regression model
where control subjects were used as the training set, i.e., the
normal, not disease-related, age and gender related differences in
the classification features were removed. Feature selection was
then carried out on the corrected feature sets using stepwise
regression [51].
We used two subsets to perform classification:
I. All 834 available baseline images described in the subjects
section
II. 509 baseline images used by Cuingnet et al. [29] and detailed
in their publication.
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ROIs and evaluation strategy used for the two datasets
respectively.
Dataset I. In order to perform the study using cross-
validation in the full dataset, it was divided into three equally
sized parts. One part was used to perform the statistical tests for
the CTH and TBM features, and the remaining two parts were
used to evaluate the classification accuracy. This was repeated
three times so that each part was once used to perform the
statistical tests. Afterwards, the results of the three repetitions were
averaged. The classification accuracy was evaluated using leave-N-
out cross validation on those subjects not included in the statistical
tests. Five percent of the evaluation subjects were regarded as the
test set, and the remaining 95% of the subjects were used to train a
classifier which was then applied to the test set. This was repeated
table-1-caption100 times, each time selecting randomly the test set
subjects. Finally, the results of the 100 repetitions were averaged.
Consequently, in overall, the classification evaluation was
performed using 300 (3|100) repetitions, and the results
presented in this paper are the average values of all these
classifications.
Dataset II. Statistical ROIs for CTH and TBM feature
extraction were calculated from the 325 baseline images that are
not part of dataset II. In order to allow direct comparison of
classification accuracy with the work by Cuingnet et al. [29],
separate training and testing sets for the different comparisons
were defined using the exact sub-groups reported in their
manuscript. Around 50% of all subjects are used to train the
different types of classifiers and the reported results are based on
classifying the remaining subjects.
Classification methods
We used two different widely used methods to perform
classification based on individual features and their combination:
Figure 1. 2D manifold embedding of a set of images acquired from healthy controls (red) and subjects with AD (blue).
doi:10.1371/journal.pone.0025446.g001
Figure 2. Results for voxelwise t-tests for statistically significant group differences with features extracted from TBM.
doi:10.1371/journal.pone.0025446.g002
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analysis (LDA) is a widely used technique to find a linear
combination of features to best separate several classes [52]. In this
work we used LDA as implemented in the classify function in
Matlab with a multivariate normal density model with unin-
formative priors (p=0.5).
Support vector machines (SVM). Support vector machines
use training data to find a separating hyperplane in the n-
dimensional training space that best separates two subject groups
[53]. Test subjects are then classified according to their position
relative to the defined hyperplane in the n-dimensional feature
space. We used the libSVM library to perform the analysis. The
radial basis function kernel was selected based on the guidelines
provided by the libSVM library (Software available 2.3.2011 at
http://www.csie.ntu.edu.tw/cjlin/libsvm).
Results
We used both classification methods to measure classification
accuracy based on individual features as well as the combination of
all features. The results for the comparisons HC vs AD, HC vs P-
MCI and S-MCI vs P-MCI in the full ADNIdatabase arepresented
in Tables 3, 4 and 5 respectively. Presented are classification
accuracy (CCR), sensitivity (SEN) and specificity (SPE). Further-
more, the 95% confidence interval for the classification accuracy is
estimated based on the multiple classification runs. Statistically
significant improvements achieved when combining all features are
marked with { (pv0.0001). To test for significance, unpaired t-tests
were carried out between distribution estimates for the correspond-
ing classification rates based on the multiple runs. All estimated
distributions passed a normality test using a Kolmogorov-Smirnov
test at a~0:05.
For direct comparison with work presented by Cuingnet et al.
[29], we performed classification based on the training- and testing
sets defined in their manuscript as described above. S-MCI and P-
MCI groups are defined in the same way as in the original
publication. Sensitivity and specificity values for the classification
in all three clinical pairings are reported in Table 6. Following the
clear advantage for LDA in the performance on the full dataset,
we only report results with this classifier for dataset II.
Discussion
In this study we assessed the automatic diagnostic capabilities of
4 structural MRI features (MBL, HC, CTH, TBM) separately and
combined in 834 baseline images acquired in the ADNI study.
When applied separately, TBM provided the overall best results,
closely followed by MBL. Combining all features improved
the results in all study experiments. Our results show how a
combination of different MRI-based features can improve results
based on only one measurement, resulting in a more powerful and
stable classifier. The most significant improvement of the combination
Figure 3. Results for t-tests for statistically significant group differences based on cortical thickness measurements.
doi:10.1371/journal.pone.0025446.g003
Table 2. Features used in the study.
Method No of features Description
Hippocampal volume (HV) 1 total volume of left and right hippopcampus
Cortical thickness 9 (HC vs AD) average cortical thickness within a ROI defined based on group-level statistical analysis
(CTH) 7 (HC vs P-MCI)
8 (S-MCI vs P-MCI)
Tensor-based morphometry (TBM) 84 average Jacobian of atrophic voxels within a ROI, weighted based on voxel-wise p-values
Manifold-based learning (MBL) 20 coordinates of a subject in a low-dimensional manifold space learned from pairwise image
similarities
doi:10.1371/journal.pone.0025446.t002
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with 5% units followed by 3 and 2% units for S-MCI vs P-MCI and
HC vs AD, respectively. These improvements lead to 20, 12 and 9
subjects more being correctly classified respectively when using the
combined feature set as compared to the best single feature for every
comparison. Comparing two classification approaches based on LDA
and SVMs resulted in a clear advantage of the former.
Several studies reported classification results using single MRI
methods for the HC/AD classification (Table 7). Liu et al. [24]
reported SEN/SPE of 92/90 in the classification of HC/AD
subjects using regional cortical volumes in the AddNeuroMed
dataset. McEvoy et al. [26] report a CCR of 89 on images from
the ADNI database using features from cortical thickness and
structural volumes. Vemuri et al. [54] present a SEN/SPE of 86/
86 on 380 subjects using the STAND score. In our study the
results obtained with single methods are lower (71–90) but almost
identical when the methods were combined. It should be noted,
however, that Liu and colleagues did not use cross-validation or
separate training/testing sets when producing the results which
could lead to overestimation of the results in a dataset outside the
study cohort. Gerardin et al. [23] acquired a high SEN/SPE of
96/92 by using hippocampal shape analysis, but the number of
subjects (25 HC, 23 AD) was quite low in order to produce results
with good generalizability. Westman et al. [55] reported a CCR of
82 for HC vs AD classification and 73 for HC vs P-MCI
classification by using various regional brain volumes. Our results
are substantially more accurate, the group sizes are larger and
clinical follow-up time is one year longer. Chupin et al. [21]
reported SEN/SPE of 75/77 (hippocampal volume) and Querbes
et al. [27] a CCR of 85 (cortical thickness), both lower than the
results acquired with the combination of features or TBM features
independently in our study.
Varying results concerning AD prediction (S-MCI/P-MCI
classification using baseline measurements) have been published
(Table 7): Querbes et al. [27] reported a CCR of 73, Liu et al. [25]
a SEN/SPE of 76/68, Chupin et al. [21] reported a SEN/SPE of
60/65 and Davatzikos et al. [15] SEN/SPE of 95/38. Our results
with separate and combined baseline features lie in the range of
these results (SEN/SPE 63/67, 64/66 and 67/69 when using HV,
MBL and the combined features, respectively).
There can be several explanations for the variation in the
reported results. A majority of the studies in this field have used
different statistical methods and MRI feature extraction strategies
on different datasets, which makes a comparison of the results
complicated. Also the variation in the size of the study samples and
the use (or ignoring) of cross-validation or separate training/testing
sets are important factors, which both have crucial impact on the
reliability and generalizability of the results. In Lo ¨tjo ¨nen et al.
[36], we demonstrated that choosing from a population of 350
cases several times 2/3 for the training set and 1/3 for the test set
and using hippocampus volume as a classification feature can lead
to any classification accuracy between 53% and 77%. This
observation is also confirmed by the high confidence intervals for
the classification accuracies reported in Tables 3, 4 and 5. This
shows that a fair comparison of methods based on the classification
accuracy is difficult if not exactly the same data and classification
approaches are used. Furthermore, since the ADNI study is still
ongoing, several subjects labeled as S-MCI will progress in the
future to the P-MCI group.
A recent study with a subset of ADNI subjects assessed the
classification performance of several structural MRI methods in
experiments comparable to our investigation [29]. Reported
Table 3. Classification results for HC vs AD.
Feature LDA SVM
CCR [95% CI] SEN SPE CCR [95% CI] SEN SPE
MBL 85{ [64 100] 87 83 85 [64 100] 87 83
HV 81{ [57 100] 81 79 81{ [57 100] 84 77
CTH 81{ [64 100] 89 71 82{ [57 100] 90 73
TBM 87{ [71 100] 90 84 87 [71 100] 89 84
All 89 [71 100] 93 85 86 [71 100] 94 78
{means statistically significant different from the combined results with
pv0.0001. CCR=Correct classification rate, SEN=Sensitivity, SPE=Specificity.
doi:10.1371/journal.pone.0025446.t003
Table 4. Classification results for HC vs P-MCI.
Feature LDA SVM
CCR [95% CI] SEN SPE CCR [95% CI] SEN SPE
MBL 78{ [54 100] 81 75 77{ [54 92] 84 69
HV 76{ [54 92] 77 76 78 [54 92] 83 71
CTH 77{ [54 100] 85 65 77 [54 100] 89 62
TBM 79{ [62 100] 82 76 80{ [62 100] 85 74
All 84 [62 100] 86 82 82 [62 100] 93 67
{means statistically significant different from the combined results with
pv0.0001.
doi:10.1371/journal.pone.0025446.t004
Table 5. Classification results for S-MCI vs P-MCI.
Feature LDA SVM
CCR [95% CI] SEN SPE CCR [95% CI] SEN SPE
MBL 65{ [36 86] 64 66 65{ [43 86] 77 48
HV 65{ [36 86] 63 67 62 [36 86] 83 33
CTH 56{ [29 86] 63 45 59 [36 79] 96 03
TBM 64{ [36 86] 65 62 64{ [36 86] 77 44
All 68 [43 93] 67 69 60 [36 86] 92 14
{means statistically significant different from the combined results with
pv0.0001.
doi:10.1371/journal.pone.0025446.t005
Table 6. Classification results based on a subset of ADNI that
was previously used for classification by Cuingnet et al. [29].
Feature HC vs AD HC vs P-MCI S-MCI vs P-MCI
SEN SPE SEN SPE SEN SPE
M B L 9 07 4 8 49 2 5 57 6
HV 80 69 75 76 63 70
C T H 8 57 5 8 65 9 7 23 5
T B M 9 37 6 9 08 4 6 35 9
A l l 9 47 6 9 48 9 6 95 4
doi:10.1371/journal.pone.0025446.t006
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73/85 (HC vs P-MCI). While most methods tested did not exceed
the accuracy of a random classifier for the discrimination between
S-MCI and P-MCI, the best results reported for this task were a
SEN/SPE of 62/69 when using hippocampal volume. To allow a
direct comparison of the results reported by Cuingnet et al. [29],
we evaluated our features on the exact same training- and testing
sets used in their paper. This direct comparison shows that our
results compare favourably to other, established methods in
neuroimaging. For HC vs AD classification, individual features in
our study give more sensitive but less specific results than most
methods in the previous publication. Combining all features gives
an overall better classification accuracy than the majority of
previously tested methods. Our results on the combined feature set
furthermore outperform the majority of methods tested by
Cuingnet et al. [29] when predicting MCI conversion as well as
all methods for the classification between HC and P-MCI. A
significant difference in classification accuracy can be observed
between the full ADNI dataset and this smaller subset used for
comparison with previous work. Reasons may include a strict
separation into trainin- and testing sets which may result in less
generalisability as well as the shorter follow-up period that was
considered to define progression to AD.
Some studies have also combined different biomarkers (CSF,
MRI, PET) with the idea of measuring different aspects of AD
pathology and thus improve the classification accuracy. Hinrichs
et al. [14] improved their HC/AD classification CCR by a few %
units to 81 by combining MRI and PET. Eckerstro ¨m et al. [16]
studied the separation of a unified HC/S-MCI group from P-MCI
group with CSF proteins and manual hippocampal volumes. They
found CSF to be superior to MRI (SEN/SPE of 95/79 vs 86/66)
while the combination performed best (SEN/SPE 90/91).
However, it should be noted that the study sample in that
particular study was small (a total of 68 subjects) and neither cross-
validation or separate training/testing sets were used in order to
ensure good generalizability of the results. In Kohannim et al.
[17], the improvement from using multiple biomarkers was not
significant and Davatzikos et al. [15] reported marginal improve-
ments which, however, may be related to the fact that results with
only one biomarker were not very good to begin with.
Considering solely the classification accuracies of the present
study and those reported in literature, it seems questionable if the
collection of several biomarkers is worth the effort and resource. A
combination of different features extracted from a single MRI
seems to provide results that are comparable or better than those
obtained with other or multiple biomarkers. In a clinical point of
view, this is interesting since it means that a single MRI scan
provides not only aid to differential diagnostics of cognitive
impairment, but also reliably describes a persons phase in the HC/
AD continuum. MRI is also widely available, non-invasive and
often useful in the differential diagnostics of memory problems
thus making it a compelling option as the first biomarker that
would be obtained from a patient with mild memory problems.
However, a comprehensive differential diagnostics between AD
and non-AD cognitive impairments will still require assessment of
various different biomarkers. Also, it should be noted that the
computational techniques used in this paper are not widely
available in the clinical environment and thus limit their usage in
the clinical work at present.
Strengths of the presented study are i) the use of multiple
features extracted from one imaging modality, ii) large groups, iii)
rigorous validation process of the results using cross-validation,
and iv) results comparable or better than the ones published so far.
Our study has also some limitations that should be mentioned.
The results are obtained from a single (although collected from
multiple sites) cohort and should be also validated in other cohorts.
A longer clinical follow-up time would be needed to see if the
classification results of S-MCI/P-MCI experiment changed when
more of the MCI subjects converted to AD. Furthermore, the
ADNI study does not provide postmortem pathological confirma-
tion of the clinical status. With this limitation, individual subjects
might be wrongly categorized. Although a rigorous validation
process was used, optimally we need to establish standardized cut-
offs that would be well generalizable to other cohorts outside
ADNI. That is, however, beyond the possibilities of this study and
will require vast standardization and validation procedures. Also,
the CTH pipeline had problems especially with severely atrophied
brains or MRI scans with poor image quality. A more robust
pipeline would be desirable in order to guarantee a more reliable
feature extraction.
Table 7. Classification results of healthy control (HC), mild cognitive impairment (MCI) and Alzheimer’s disease subjects reported
in the recent literature.
Study N Features HC vs AD HC vs P-MCI S-MCI vs P-MCI
CCR SEN SPE CCR SEN SPE CCR SEN SPE
Liu et al. [24] 333 Cortical volumes 91 92 90 - -----
Gerardin et al. [23]* 70 Hippocampus shape 94 96 92 - -----
Chupin et al. [21]* 605 Hippocampus volume 76 75 77 - - - 64 60 65
Querbes et al. [27]* 382 Cortical thickness 85 - - - - - 73 75 68
Liu et al. [25] 312 Amygdala/caudate volumes ------6 9 7 6 6 8
Davatzikos et al. [15]* 356 SPARE-AD index ------5 6 9 5 3 8
Cuingnet et al. [29]* 509 Various - 81 95 - 73 85 - 62 69
Hinrichs et al. [14]* 159 MRI & PET 81 - - 60 92 14 - - -
Westman et al. [55] 351 Various volumes 82 - - 73 -----
McEvoy et al. [26]* 398 Cortical thickness/various volumes 89 83 93 - -----
Vemuri et al. [54] 380 STAND score - 86 86 - -----
N=Number of study subjects,
*=ADNI dataset.
doi:10.1371/journal.pone.0025446.t007
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